Ointment for treatment of dermatomycosis in animal and human

FIELD: veterinary science, medicine, pharmacy.

SUBSTANCE: invention relates to agents used in treatment of dermatomycosis in animals and humans. Ointment for treatment of dermatomycosis in animals and humans comprises acetylsalicylic acid, 5% iodine alcoholic solution and glycerol taken in the definite ratio of components. Invention enhances effectiveness of treatment, decreases time in treatment of dermatomycosis and prevents appearance of new foci of diseases and relapses.

EFFECT: enhanced effectiveness of treatment.

6 ex

 

The invention relates to the field and veterinary medicine, namely, Mycology, and can be used for treatment of ringworm in animals and humans. Known chemotherapeutic drugs for oral administration having fungistatic and fungicidal activity against various dermatophytes, such as griseofulvin, nizoral, terbinafine and other their Mechanism of action is associated with inhibition of the processes of protein synthesis, the defeat of the cytoplasmic membrane of fungal cells and impaired synthesis of ergosterol [1, 2].

These chemotherapy drugs have side effects and have a number of significant contraindications, which complicates their use in the treatment of dermatomycoses.

Also known antifungal preparations (econazole, mikozolon, isoconazole, nitrofungin and others) used for external application for the local treatment of fungal infections of the skin [3]. The disadvantage of these tools is the presence of unwanted side effects in the form of itching, burning sensation, allergic reactions and other

These drugs and other analogues offer ointments, as a rule, delaying the treatment for 1-3 months. In addition, the treatment of the above mentioned drugs are often temporarily deafened disease and relapses occurred, but on the other site of the body of the animal or human.

Closest to the technical essence is the ointment "Black" for the treatment of Aronson and ringworm containing (machine hours) pure Ichthyol - 1.0, birch tar, - 1.0, phenol - 1,0, acetylsalicylic acid and 0.5, the fraction of SDA-3 - 0,5, glycerol - 6,0 [4]. Although it contains in addition to acetylsalicylic acid for another four component has antiseptic and antifungal action, it has low efficiency, causes skin irritation due cauterizing action of phenol, inconvenient to use, since, with black color, stain the surrounding objects and has a pungent smell. The duration of treatment of ringworm ointment "Black" is 10 days.

The prior art is not known ointment for treatment of ringworm in animals and humans, which would ensure recovery within 3-5 days after the start of treatment.

Thus, the present invention is the creation of ointments which, firstly, reducing the duration of treatment, and secondly, to prevent the emergence of new foci of the disease and recurrence.

To solve this problem it was necessary to develop an effective and convenient to use an ointment for the treatment of dermatomycoses.

The technical result of the present invention is the reduction of terms of treatment and prevention of the emergence of new foci of the disease and recurrence. The essence of the invention is ostoic is what ointment for treatment of ringworm animal rights contains, wt%:

acetylsalicylic acid61-63
5% alcoholic solution of iodine1-2
glycerinthe rest of it.

Although all the components of the claimed ointment is well known and there are indications that they individually are part of some antifungal drugs from the prior art not known to the drug containing all three components in the proposed ratios. Use for the treatment of ringworm in animals and humans ointment that has the specified qualitative and quantitative composition, allows to achieve the recovery of the patient for 3-5 days, precluding the occurrence of new lesions and relapses. It is in this combination and ratio of components is manifested unknown and unobvious from the prior art synergistic effect, providing increased efficiency, reduction of terms of treatment of ringworm and prevent the appearance of new foci of the disease and recurrence

Ointment for the treatment of ringworm in animals and humans is prepared as follows.

In a porcelain mortar grind 61-63 g of acetylsalicylic acid, gradually add 1-2 g of 5% alcohol solution of iodine and glycerin to 100, the donkey short excerpts ointment ready to use. The ointment is a gray-purple homogeneous mass buttery consistency and odourless. The ointment should be stored in a place protected from light, at temperatures from 2 to 10°S. Masi was given the name "Ointment "Ben-ants".

Ointment "Ben-ants" is used for treatment of ringworm in animals and humans,including ringworm, and eczema is caused by a fungus Altenaria tenuis ("summer itch"). Ointment is effective in the treatment of other fungal skin diseases. When applying the ointment directly on the affected skin area rapid regeneration of skin cells and destruction of pathogens at the site of infection. Unlike ointments "Black ointment "Ben-ants" very well, absorbs quickly into the skin and prevents the spread of the fungus to other areas of the skin.

To ensure the ointment is applied with a spatula on the affected skin and thoroughly rubbed in 2-3 minutes a day 1 time a day for 3 days. In the case of severe disease after the third day one day pass and on the 5th day, the procedure was repeated. During treatment, the size of affected areas cease to increase in the treated areas disappear "scales" and skin color turns from bright pink to light pink or white. Microscopy of scrapings from the treated plots and crops on agar Saburo confirm the absence of the pathogen. Growth in the OS on the affected skin area starts at 7 day 10 after the start of treatment.

Example 1. Ointment for the treatment of ringworm in animals and humans was prepared as follows. In a porcelain mortar rubbed 62 g of acetylsalicylic acid was gradually added 37 g of glycerol and 1 g of a 5%alcohol solution of iodine. After a short aging ointment was a gray-purple homogeneous mass buttery consistency odourless and was ready to use.

Example 2. Male Metis, nicknamed "Richie", age 3 years, the affected area on the face of the nose on the left side with a diameter of about 3, see Diagnosis of trichophytosis, the diagnosis is confirmed by microscopy and culture on agar Saburo, pathogen - Tr.canis.

The ointment prepared in example 1, was applied with a spatula on the affected skin and thoroughly rubbed in 2-3 minutes a day 1 time a day for 3 days. During treatment, the size of the affected area was not increased in the treated area disappeared "scales" and skin color turned from bright pink to light pink. During treatment allergic reactions were observed. Microscopy of scrapings from the treated plots and crops on agar Saburo confirmed the absence of the pathogen. On the sixth day of the treated area, and resumed growth of wool.

Example 3. Dog breed Azamat, nicknamed "Myrtle", age 2 years, the affected areas at the Mor is in the area of the bridge of the nose and upper lip with a diameter of about 3-4 cm Before enrolling in a veterinary clinic dog was sick for about a month. The diagnosis of trichophytosis, the diagnosis is confirmed by microscopy and culture on agar Saburo, pathogen - Tr.canis.

The ointment prepared in example 1, was applied with a spatula on the affected skin and thoroughly rubbed in 2-3 minutes a day 1 time a day for 3 days. Because after the third day of treatment in the area of the bridge of the nose on the skin remained "flakes", missed one day and on the 5th day of the procedure repeated. During treatment, the size of the affected area was not increased in the treated area disappeared "scales" and skin color turned from bright pink to light pink. During treatment allergic reactions were observed. Microscopy of scrapings from the treated plots and crops on agar Saburo confirmed the absence of the pathogen. On the sixth day of the treated area, and resumed growth of wool.

Example 4. Treatment of Microsporum. Cat home mongrel, nicknamed "Fluff", age 4 years, three of the affected area with a diameter of 0.5-1 cm on the muzzle, forehead, nose and upper lip. The diagnosis of microsporia, the diagnosis is confirmed by microscopy and culture on wort agar. Pathogen Microsporum gypseum. Before treatment around the affected foci were vestigal wool width 1 see the Ointment was applied with a spatula on the affected skin and carefully rubbed into the Techa is their 2-3 minutes a day 1 time a day for 3 days. During treatment, the size of the affected areas were not increased in the treated areas disappeared "scales" and skin color turned from bright pink to light pink. Microscopy of scrapings from the treated plots and crops on agar Saburo confirmed the absence of the pathogen. During treatment allergic reactions were observed. On the sixth day of the treated area, and resumed growth of wool.

Example 5. Patient T., aged 25 years, the affected area of the skin on the outer surface of the forearm with a diameter of about 5 cm and around multiple small foci with a diameter of from 1 to 3 cm, the diagnosis of microsporia. From scraping from the affected area of the skin selected pathogen - Tr.canis, the diagnosis is confirmed by microscopic studies, the crops on the environment Saburo and fluorescent method.

The ointment prepared in example 1, was applied with a spatula on the affected skin and thoroughly rubbed in 2-3 minutes a day 1 time a day for 3 days. During treatment, the size of the affected areas were not increased in the treated areas disappeared "scales" and skin color turned from bright pink to light pink. Microscopy of scrapings from the treated plots and crops on agar Saburo confirmed the absence of the pathogen. During treatment allergic reactions were not observed.

Example 6. Hurt Is Acting, age 12 years, the affected area of the scalp with a diameter of about 7 cm and 2 affected area on the right hand with a diameter of 1-2 cm, the diagnosis of microsporia. From scraping from the affected area of the skin selected pathogen - M.canis, the diagnosis is confirmed by microscopic studies, the crops on the environment Saburo and fluorescent method.

Before treatment on the affected area on the head and around the width of 1-1,5 cm was vestigal hair. The ointment prepared in example 1, was applied with a spatula on the affected skin and thoroughly rubbed in 2-3 minutes a day 1 time a day for 3 days. During treatment, the size of the affected areas were not increased in the treated areas disappeared "scales" and bright pink skin color changed to light pink in hand and white on the head. Microscopy of scrapings from the treated plots and crops on agar Saburo confirmed the absence of the pathogen. During treatment allergic reactions were observed. On the tenth day on the treated plot on his head began to grow hair.

Proposed ointment for treatment of ringworm in animals and humans is convenient, reliable and effective, therapeutic effect occurs much faster than when using known drugs.

Sources of information

1. The vishkovsky GL and other RLS - encyclopedia of drugs is", M: RLS-2000", 2000, s, 635, 880.

Caromatic A.B. Reference to the use of antibiotics and other chemotherapeutic drugs. Kiev: high school, 1983, Istanbul, p. 378.

3. Mashkovsky PPM Medicines. 2 PM: New wave, 2000, s-365.

4. RF patent №2153327, 27.07.2000.

Ointment for the treatment of ringworm in animals and humans containing acetylsalicylic acid and glycerin, characterized in that it contains an additional 5% alcohol solution of iodine, in the following ratio, wt.%:

Acetylsalicylic acid61-63
5% Alcoholic solution of iodine1-2
GlycerinRest



 

Same patents:

FIELD: cosmetics.

SUBSTANCE: invention relates to compositions stimulating hair growth that comprise minoxidil as an active component. Proposed compositions don't show precipitation of crystals at lower temperatures and possess high stability. Preparations comprising 10-50 wt.-% of water and 3-6 wt.-% of minoxidil involve additionally 8-30 wt.-% of polyatomic alcohol, 70 wt.-% of ethanol or less and show pH value 5.5-6.5. Invention provides the development of preparation with high concentration of minoxidil that is stable in storage and without precipitation of crystals even at low temperatures and a method for prevention for precipitation of minoxidil.

EFFECT: improved and valuable properties of compositions.

10 cl, 8 tbl, 5 ex

FIELD: medicine and biopharmacology.

SUBSTANCE: claimed biotransplant contains culture of genetically non-modified mesenchyme stem cells (MSC), including fibroblasts of hair follicule dermal papillae, epithelial cells including ones obtained from hair follicle stem niche. Biotransplant is used in intradermal administration. Method for alopecia treatment includes intradermal administration of biotransplant containing from 10 to 100 millions cells to patient, in procedure room by micropapulic method. Biotransplant is administered in physiological solution with concentration from 1 to 10 millions per 1 ml. Total transplant amount is 1-10 millions depending on lesion area and type of alopecia.

EFFECT: method for alopecia treatment with high reproducibility.

12 cl

FIELD: medicine and biopharmacology.

SUBSTANCE: claimed biotransplant contains culture of genetically non-modified mesenchyme stem cells (MSC), fibroblasts including epithelial cells. Biotransplant is used in intradermal administration. Biotransplant is administered topically in physiological solution with concentration from 1 to 10 millions per 1 ml. Total transplant amount is 1-10 millions depending on defect area.

EFFECT: treatment method with high reproducibility.

14 cl

Healing agent // 2271814

FIELD: medicine, pharmacy.

SUBSTANCE: invention represents a healing agent used for close and treatment of suppurative-necrotic and infected wounds, burns, trophic ulcers. Proposed composition comprises the following components taken in the required ratio: water-soluble chitosan of natural origin, polyalkyleneguanides phosphopag and biopag, proteolytic enzymes pepsin and collagenases, ascorbic acid and anesthetic agent. Agent shows the combined wound-healing, bacteriostatic and immunostimulating properties, it stimulates regenerative-reparative processes and accelerates growth of wound healthy cells. Also, agent decreases number of little use and/or expensive components used in preparing wound-healing agents.

EFFECT: improved and valuable medicinal properties of agent.

7 cl, 2 tbl, 10 ex

FIELD: medicine, dermatology, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical gel composition for applying on skin. The composition comprises at least one vitamin D or analog of vitamin D, at least one corticosteroid, at least one solvent and an excipient enhancing viscosity. Viscosity value of the composition is in the range from 5 mPa x s to 500 mPa x s. The composition is designated for treatment of psoriasis and associated states in humans. The composition is suitable for applying on skin, shows the improved absorption and stable at 40°C in storage for 3 months.

EFFECT: improved and valuable properties of composition.

22 cl, 2 tbl, 1 ex

FIELD: medicine, venereology.

SUBSTANCE: invention relates to a method for topical treatment of papilloma viral infection of urogenital way in women. For this aim a medicinal mixture consisting of tisol and interferon taken in the ratio 100 IU of interferon per 1 g of tisol is applied on damaged regions of urogenital way mucosa in women for 2 h. In 24 h procedure is repeated, and treatment course is 10 procedures. Method provides ceasing viral secretion and absence of by-side effect of interferon therapy method proposed.

EFFECT: improved method for infection treatment.

1 ex

FIELD: medicine, cosmetology.

SUBSTANCE: one should carry out therapy including 3 stages, moreover, at the first 1-2-mo-long stage one should interrupt acute acne process and treatment of urogenital infection due to applying sanitation and antibacterial skin protection, at the second 3-5-mo-long stage it is necessary to conduct hygienic care for patient's skin by applying methods of ultrasound and chemical peeling to remove neoplasms caused by human papilloma virus, remove nevuses in operational area, perform treatment of keloid cicatrices to remove vaginal dysbiosis and urogenital diseases, at the third stage one should fulfill mechanic dermabrasion followed by post-operational 1-2-mo-long care, moreover, as antibacterial preparations during sanitation one should apply butol, after sanitation - butol and baneocin, and after epithelization of acne foci and vaginal epithelium - butol and butolol applied in pre-menstrual period not combining the use of the preparations mentioned with treating surface with alcohol- and metal-containing solutions. The present innovation provides decreased number of relapses due to interrupting inflammatory processes and normalizing diybiosis.

EFFECT: higher efficiency of therapy.

1 ex, 1 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivative of triazaspiro[5.5]undecane of the formula (I): wherein R1 means compound of the formula (1): or (2): wherein G represents a bond, (C1-C4)-alkylene, (C2-C4)-alkenylene or -CO-; ring A represents: (1) C5-10-membered mono- or bicarbocyclic ring or (2) 5-10-membered mono- or bicyclic heterocycle comprising 1-2 nitrogen atoms and/or 1-2 oxygen atoms; substitute R6 means the following values: (1) (C1-C4)-alkyl, (2) halogen atom, (3) nitrile group, (4) trifluoromethyl group and others; R2 represents: (1) (C1-C4)-alkyl, (2) (C2-C4)alkynyl or (3) (C1-C4)-alkyl substituted with a substitute represented in claim 1 of the invention claim; each R3 and R4 represents independently: (1) hydrogen atom, (2) (C1-C4)-alkyl or (3) (C1-C4)-alkyl substituted with 1-2 substituted taken among: (a) Cyc 2 and (b) hydroxy-group (wherein Cyc 2 represents (1) C5-6-membered monocarbocyclic ring or (2) 5-6-membered monocyclic heterocycle comprising 1-2 nitrogen atoms and/or one oxygen atom), or R3 and R4 form in common group of the formula: wherein R26 represents (C1-C4)-alkyl or Cyc 2; R5 represents hydrogen atom or (C1-C4)-alkyl, its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to pharmaceutical composition inhibiting HIV, regulator of chemokine/chemokine receptor and agent used in treatment and prophylaxis of some diseases, such as inflammatory diseases, asthma, atopic dermatitis, nettle rash, allergic diseases, nephritis, hepatitis, arthritis and other diseases that comprise as an active component above described compound of the formula (I) or its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof, and to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane hydrochloride and pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of derivative and composition.

16 cl, 32 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivative of triazaspiro[5.5]undecane of the formula (I): wherein R1 means compound of the formula (1): or (2): wherein G represents a bond, (C1-C4)-alkylene, (C2-C4)-alkenylene or -CO-; ring A represents: (1) C5-10-membered mono- or bicarbocyclic ring or (2) 5-10-membered mono- or bicyclic heterocycle comprising 1-2 nitrogen atoms and/or 1-2 oxygen atoms; substitute R6 means the following values: (1) (C1-C4)-alkyl, (2) halogen atom, (3) nitrile group, (4) trifluoromethyl group and others; R2 represents: (1) (C1-C4)-alkyl, (2) (C2-C4)alkynyl or (3) (C1-C4)-alkyl substituted with a substitute represented in claim 1 of the invention claim; each R3 and R4 represents independently: (1) hydrogen atom, (2) (C1-C4)-alkyl or (3) (C1-C4)-alkyl substituted with 1-2 substituted taken among: (a) Cyc 2 and (b) hydroxy-group (wherein Cyc 2 represents (1) C5-6-membered monocarbocyclic ring or (2) 5-6-membered monocyclic heterocycle comprising 1-2 nitrogen atoms and/or one oxygen atom), or R3 and R4 form in common group of the formula: wherein R26 represents (C1-C4)-alkyl or Cyc 2; R5 represents hydrogen atom or (C1-C4)-alkyl, its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to pharmaceutical composition inhibiting HIV, regulator of chemokine/chemokine receptor and agent used in treatment and prophylaxis of some diseases, such as inflammatory diseases, asthma, atopic dermatitis, nettle rash, allergic diseases, nephritis, hepatitis, arthritis and other diseases that comprise as an active component above described compound of the formula (I) or its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof, and to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane hydrochloride and pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of derivative and composition.

16 cl, 32 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to derivative of triazaspiro[5.5]undecane of the formula (I): wherein R1 means compound of the formula (1): or (2): wherein G represents a bond, (C1-C4)-alkylene, (C2-C4)-alkenylene or -CO-; ring A represents: (1) C5-10-membered mono- or bicarbocyclic ring or (2) 5-10-membered mono- or bicyclic heterocycle comprising 1-2 nitrogen atoms and/or 1-2 oxygen atoms; substitute R6 means the following values: (1) (C1-C4)-alkyl, (2) halogen atom, (3) nitrile group, (4) trifluoromethyl group and others; R2 represents: (1) (C1-C4)-alkyl, (2) (C2-C4)alkynyl or (3) (C1-C4)-alkyl substituted with a substitute represented in claim 1 of the invention claim; each R3 and R4 represents independently: (1) hydrogen atom, (2) (C1-C4)-alkyl or (3) (C1-C4)-alkyl substituted with 1-2 substituted taken among: (a) Cyc 2 and (b) hydroxy-group (wherein Cyc 2 represents (1) C5-6-membered monocarbocyclic ring or (2) 5-6-membered monocyclic heterocycle comprising 1-2 nitrogen atoms and/or one oxygen atom), or R3 and R4 form in common group of the formula: wherein R26 represents (C1-C4)-alkyl or Cyc 2; R5 represents hydrogen atom or (C1-C4)-alkyl, its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to pharmaceutical composition inhibiting HIV, regulator of chemokine/chemokine receptor and agent used in treatment and prophylaxis of some diseases, such as inflammatory diseases, asthma, atopic dermatitis, nettle rash, allergic diseases, nephritis, hepatitis, arthritis and other diseases that comprise as an active component above described compound of the formula (I) or its quaternary ammonium salt, its N-oxide or its nontoxic salt. Also, invention relates to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane or its pharmaceutically acceptable salt and pharmaceutical composition based on thereof, and to (3R)-1-butyl-2,5-dioxo-3-((1R)-1-hydroxy-1-cyclohexylmethyl)-9-(4-(4-carboxyphenyloxy)phenylmethyl)-1,4,9-triazaspiro[5.5]undecane hydrochloride and pharmaceutical composition based on thereof.

EFFECT: valuable medicinal properties of derivative and composition.

16 cl, 32 ex

FIELD: medicine, contraception.

SUBSTANCE: invention proposes antibacterial and contraceptive compositions that comprise the following components: (1) matrix-forming substance; (2) bioadhesive substance; (3) buffer substance; (4) moistening substance, optionally; (5) preserving agent, optionally, and (6) water. Proposed compositions are suitable for their placement into vagina wherein compositions form semisolid matrix in contact with testicular fluid, cause thickening cervical mucus, form a bioadhesive layer on vagina surfaces, maintain the natural acid pH value in vagina about less 5 in the presence of testicular fluid ejected by a male and don't disturb essentially the natural microbiological balance in vagina. Compositions and methods decrease and/or prevent transfer of diseases transferring by sexual way and act as vaginal contraceptives with less adverse effect as compared with conventional vaginal contraceptives and can be used therefore for a long time. Compositions and methods are simple for using and don't require a physical device for their retention into vagina during using.

EFFECT: improved and valuable properties of compositions and methods.

36 cl, 17 tbl, 11 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to an agent for topical using used in treatment of joint diseases. The proposed agent comprises glucosamine salt, chondroitin sulfate and dimethylsulfoxide incorporated into an acceptable ointment base. Invention provides enhancing effectiveness due to using low-molecular saccharides that results to elevating diffusion delivery rate of the substance to the joint zone and providing the achievement of synergistic effect in treatment of joint diseases.

EFFECT: enhanced effectiveness and valuable medicinal properties of agent.

2 cl, 3 ex

FIELD: medicine, pharmacy.

SUBSTANCE: invention relates to preparations for external using in treatment of joint diseases. The proposed agent comprises a saccharide - glucosamine salt and dimethylsulfoxide incorporated into an acceptable ointment base. Invention provides enhancing effectiveness of agent due to using low-molecular saccharides that results to the elevating diffusion delivery rate of active substance to the join zone.

EFFECT: improved and valuable properties of agent.

2 cl, 5 ex

FIELD: medicine, dermatology, pharmacy.

SUBSTANCE: invention relates to a pharmaceutical gel composition for applying on skin. The composition comprises at least one vitamin D or analog of vitamin D, at least one corticosteroid, at least one solvent and an excipient enhancing viscosity. Viscosity value of the composition is in the range from 5 mPa x s to 500 mPa x s. The composition is designated for treatment of psoriasis and associated states in humans. The composition is suitable for applying on skin, shows the improved absorption and stable at 40°C in storage for 3 months.

EFFECT: improved and valuable properties of composition.

22 cl, 2 tbl, 1 ex

FIELD: medicine, endocrinology, pharmaceutical technology, pharmacy.

SUBSTANCE: invention relates to nateglynide-containing preparation used in treatment of diabetes mellitus that comprises nateglynide as an active component and a carrier wherein nateglynide in amorphous form and indicated carrier represents hydrophilic material. Amorphous property of crystalline nateglynide is provided by the following methods: 1) by dissolving nateglynide crystals in pharmacologically acceptable solvent in common with hydrophilic materials taken among the group consisting of water-soluble polymers, water-swelling polymers, sugar alcohols and salts followed by granulation in fluidized layer, granulation by stirring at high rate, drying by spraying and process for coat applying for granulation of amorphous nateglynide; 2) by mixing nateglynide crystals with hydrophilic materials taken among the group of water-soluble polymers, water-swelling polymers, sugar alcohols and salts and the following application of the high shift force to the prepared mixture; 3) by mixing nateglynide crystals with hydrophilic materials taken among the group of water-soluble polymers, water-swelling polymers, sugar alcohols and salts and the following plasticizing the prepared mixture in melt by heating and milling at cooling; 4) by dissolving nateglynide crystals in pharmacologically acceptable liquid additives wherein liquid additives represent water-soluble polymers that are liquid at 37°C. Using amorphous nateglynide allows preparing the nateglynide preparation with immediate release wherein the dissolving rate of medicinal agents is high and without crystalline transition during preparing or preserving preparations.

EFFECT: valuable pharmaceutical properties of preparation.

6 cl, 3 tbl, 9 dwg

FIELD: medicine, pharmacy.

SUBSTANCE: invention proposes using xenogenous oligo-and/or polyribonucleotides, namely total RNA and tRNA, as an active component of external anhydrous medicinal agent for a single treatment of skin tumor relapse (for example, basalioma) or infections caused by herpes virus and the corresponding method for treatment. The claimed external anhydrous medicinal agents decline effectively relapses of indicated diseases after a single intake.

EFFECT: enhanced effectiveness and valuable medicinal properties of agents.

5 cl, 2 ex

FIELD: veterinary science.

SUBSTANCE: the suggested preparation contains dense propolis, vegetable oil, extract out of dead bees based upon glycerol, lanolin, honeycombs' cutting off, moreover, all the components should be taken at certain quantitative ratio, weight%: honeycombs' cutting off 15-20, dense propolis 20-25, extract out of dead bees upon glycerol 7.5 -10, lanolin 20-25, vegetable oil - the rest, moreover, honeycombs' cutting off includes honey residues. The preparation in question is of high biological activity, provides shortened terms for recovery in animals and excludes allergic reactions.

EFFECT: higher efficiency for therapy.

1 cl, 8 ex

FIELD: medicine, phytotherapy, infectious diseases, pharmaceutical industry.

SUBSTANCE: invention relates to a method for preparing ointment used in erysipelas treatment. Method for preparing ointment used in erysipelas treatment involves milling washed and dried viper's-bugloss roots (Echium rubrum, Jacg, family Boraginaceae) and their extraction with melted butter under the definite conditions. Then extract is infused at stirring for a definite time, macerate is filtered off at cooling to a definite temperature and poured off. Extraction is carried out twice, vegetable raw residues are squeezed out, and prepared sap is combined with first two extracts, settled for a definite time and bottled. Method provides preparing ointment that promotes to effective treatment of erysipelas and reducing treatment period.

EFFECT: improved preparing method, valuable medicinal properties of ointment.

5 ex

FIELD: medicine, urology.

SUBSTANCE: the present innovation deals with means for external application. The suggested gel-like preparation contains hydroxyethylcellulose polymer as a gel foundation, lidocaine hydrochloride, an antiseptic component - benzalconium chloride (50%), gentamycin and water. The remedy is nontoxic and easy in application, it demonstrates no unfavorable side irritating action being of high penetrating capacity of active components.

EFFECT: higher efficiency of application.

1 cl, 1 dwg, 7 ex

FIELD: chemical-pharmaceutical industry and technology, pharmacy.

SUBSTANCE: invention relates to a method for addition of difficultly water-soluble medicinal substances to the emulsion base. Method involves preliminary preparing solid dispersions by melting a medicinal substance and polyethylene glycol-1500 in the ratio = 1:(5-5.5) by mass at temperature no causing their destruction (90-140°C). Then solid dispersions are added to emulsion bases. Invention provides enhancing the pharmaceutical availability of difficultly water-soluble medicinal substances from soft medicinal formulations by 4-50.2 times and providing the better release due to enhanced solubility and rate of dissolving medicinal substances in preparing solid dispersions. This results to reducing dose and adverse effect of the medicinal substance on the body.

EFFECT: improved method for addition and preparing.

1 tbl, 3 dwg, 5 ex

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating puerperal endometritis in cows. One should introduce the foam into uterine cavity that appears after interacting with warm water containing 10 U oxytocin and a suppository that includes medicinal substances reduced up to amorphous state. Moreover, components in a suppository are in the following ratio, g (weight%): potassium iodide 1.5 (5.4), ephedrine hydrochloride 0.5 (1.8), furacillin 0.5 (1.8), metronidazole (trichopol) 1.5 (5.4), proserine (prostigmin) 0.06 (0.2), analgin 0.5 (1.8), sodium bicarbonate 9.0 (32.7), potato starch 4.0 (14.6), common salt 1.5 (5.4), citric acid 6.9 (25), calcium stearate 0.3 (1.1), 20%-alcoholic solution of MGD-2 emulsifier or MGD-2-similar one 1.3 (4.8). The innovation provides higher efficiency of local impact of medicinal substances upon pathogenic uterine microflora.

EFFECT: higher efficiency.

1 cl, 1 tbl

Up!